istradefylline vs VG081821AC
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: adenosine A2A · full Parkinson's Disease pipeline
istradefylline · Nourianz
Marketed by Kyowa Kirin
NCT01968031 · Phase 3 · completed
This randomized, double-blind, placebo-controlled global Phase 3 trial treated 609 patients with moderate to severe Parkinson's disease and wearing-off on levodopa with istradefylline 20 mg, 40 mg or placebo for 12 weeks. The primary endpoint was change from baseline in daily OFF hours at week 12. The sponsor reports a trend toward less OFF time but no statistically significant difference from placebo for either dose, so the primary was missed. The registry posts median OFF hours by visit but no test. Source: the sponsor's topline release, which names NCT01968031.
Result from the sponsor's press release; the release gives no effect estimate or p-value.
Reported efficacy
To establish the efficacy of a 20 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.: Placebo-corrected reduction in daily OFF time at endpoint: 4.6% (equivalent to 0.7 hours), P=0.03, favoring istradefylline 20mg/day over placebo. (met)
Result source: NCT00199407
VG081821AC
Developed by Vimgreen Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07725562 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | istradefylline | VG081821AC |
|---|---|---|
| OFF time, change | 4 vs 4.2−0.2 vs placeboNCT019680317 other results
| —Trial running · NCT07725562 |
| ON time without troublesome dyskinesia, change | 10.7 vs 10.1+0.6 vs placeboNCT019680317 other results
| —Trial running · NCT07725562 |
| UPDRS Part III, change | 19.7 vs 19.4+0.3 vs placeboNCT019680317 other results
| —Trial running · NCT07725562 |
| MDS-UPDRS Part II, change | —Not posted · NCT00955526 | —Trial running · NCT07725562 |
OFF time, change
- istradefylline
- 4 vs 4.2−0.2 vs placeboNCT01968031
7 other results
- 3.8 vs 4.3 NCT01968031
- 3.8 vs 4.2 NCT01968031
- 4.3 vs 4.8 NCT01968031
- 3.8 vs 4.2 NCT01968031
- 3.5 vs 4.3 NCT01968031
- 3.8 vs 4.2 NCT01968031
- 4.1 vs 4.8 NCT01968031
- VG081821AC
- —Trial running · NCT07725562
ON time without troublesome dyskinesia, change
- istradefylline
- 10.7 vs 10.1+0.6 vs placeboNCT01968031
7 other results
- 10.7 vs 10.1 NCT01968031
- 10.7 vs 10.2 NCT01968031
- 10.2 vs 9.9 NCT01968031
- 10.5 vs 10.1 NCT01968031
- 10.5 vs 10.1 NCT01968031
- 10.5 vs 10.2 NCT01968031
- 10.5 vs 9.9 NCT01968031
- VG081821AC
- —Trial running · NCT07725562
UPDRS Part III, change
- istradefylline
- 19.7 vs 19.4+0.3 vs placeboNCT01968031
7 other results
- 19.4 vs 19.2 NCT01968031
- 20.2 vs 19.9 NCT01968031
- 20.8 vs 20.1 NCT01968031
- 19.6 vs 19.4 NCT01968031
- 19.9 vs 19.2 NCT01968031
- 20.2 vs 19.9 NCT01968031
- 20.7 vs 20.1 NCT01968031
- VG081821AC
- —Trial running · NCT07725562
MDS-UPDRS Part II, change
- istradefylline
- —Not posted · NCT00955526
- VG081821AC
- —Trial running · NCT07725562
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
VG081821AC: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. istradefylline: 4 of 4 rows · VG081821AC: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | istradefylline |
|---|---|
| Dropout rate | 9.9%20 mg/Daya NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results14%40 mg/Day NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 —20 mg or 40 mg NCT02610231 · Phase 3 |
| Discontinued due to AEs | 5%20 mg/Daya NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results10.6%40 mg/Day NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 —20 mg or 40 mg NCT02610231 · Phase 3 |
| Serious AEs | 3%20 mg/Daya NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results3.9%40 mg/Day NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 12.6%20 mg or 40 mg NCT02610231 · Phase 3 |
| Most frequent reported AEs | 20 mg/Daya dyskinesia 11.4% (placebo 6.9%) fall 6.5% (placebo 4.4%) insomnia 5% (placebo 2.5%) NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results40 mg/Day dyskinesia 16.4% (placebo 6.9%) fall 8.7% (placebo 4.4%) nausea 5.8% (placebo 1%) NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
istradefylline
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: istradefylline's landscape · VG081821AC's landscape